Rani Therapeutics Holdings Stock Analysis
| RANI Stock | USD 2.02 0.03 1.51% |
Rani Therapeutics Holdings is overvalued with Real Value of 1.86 and Target Price of 22.25. The main objective of Rani Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Rani Therapeutics Holdings is worth, separate from its market price. There are two main types of Rani Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Rani Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Rani Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Rani |
Rani Stock Analysis Notes
About 31.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.68. Rani Therapeutics recorded a loss per share of 1.05. The entity had not issued any dividends in recent years. Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company was incorporated in 2012 and is headquartered in San Jose, California. Rani Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 114 people. To find out more about Rani Therapeutics Holdings contact Talat Imran at 408 457 3700 or learn more at https://www.ranitherapeutics.com.Rani Therapeutics Investment Alerts
| Rani Therapeutics generated a negative expected return over the last 90 days | |
| Rani Therapeutics has high historical volatility and very poor performance | |
| Rani Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (33.97 M) with profit before overhead, payroll, taxes, and interest of 2.72 M. | |
| Rani Therapeutics Holdings currently holds about 98.17 M in cash with (51.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 31.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: RANI Third Quarter Update |
Rani Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Rani Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Rani Largest EPS Surprises
Earnings surprises can significantly impact Rani Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-20 | 2023-12-31 | -0.31 | -0.27 | 0.04 | 12 | ||
2024-08-06 | 2024-06-30 | -0.32 | -0.26 | 0.06 | 18 | ||
2021-11-15 | 2021-09-30 | -0.18 | -0.12 | 0.06 | 33 |
Rani Therapeutics Environmental, Social, and Governance (ESG) Scores
Rani Therapeutics' ESG score is a quantitative measure that evaluates Rani Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Rani Therapeutics' operations that may have significant financial implications and affect Rani Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Rani Stock Institutional Investors
| Shares | Lasry Marc | 2024-09-30 | 62.9 K | Motco | 2024-09-30 | 48.1 K | State Street Corp | 2024-09-30 | 42 K | Renaissance Technologies Corp | 2024-09-30 | 33.2 K | Brown Advisory Holdings Inc | 2024-09-30 | 32.9 K | Citadel Advisors Llc | 2024-09-30 | 26.9 K | Lafayette Investments, Inc. | 2024-09-30 | 19.9 K | Ubs Group Ag | 2024-09-30 | 15.7 K | Prime Capital Investment Advisors, Llc | 2024-09-30 | 11.5 K | Armistice Capital, Llc | 2024-09-30 | 2.6 M | Vanguard Group Inc | 2024-09-30 | 709.8 K |
Rani Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 116.52 M.Rani Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (1.32) | (1.39) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (2.64) | (2.51) |
Management Efficiency
Rani Therapeutics has return on total asset (ROA) of (0.5683) % which means that it has lost $0.5683 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2535) %, meaning that it created substantial loss on money invested by shareholders. Rani Therapeutics' management efficiency ratios could be used to measure how well Rani Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.62. The current Return On Capital Employed is estimated to decrease to -1.39. As of now, Rani Therapeutics' Fixed Asset Turnover is increasing as compared to previous years. The Rani Therapeutics' current Asset Turnover is estimated to increase to 0.03, while Non Current Assets Total are projected to decrease to under 6.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.00 | 1.05 | |
| Tangible Book Value Per Share | 1.00 | 1.05 | |
| Enterprise Value Over EBITDA | (1.67) | (1.75) | |
| Price Book Value Ratio | 6.58 | 6.91 | |
| Enterprise Value Multiple | (1.67) | (1.75) | |
| Price Fair Value | 6.58 | 6.91 |
Leadership effectiveness at Rani Therapeutics Holdings is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 0.114 | Return On Assets (0.57) | Return On Equity (2.25) |
Technical Drivers
As of the 2nd of December, Rani Therapeutics holds the Variance of 96.39, insignificant risk adjusted performance, and Coefficient Of Variation of (5,594). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rani Therapeutics, as well as the relationship between them.Rani Therapeutics Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Rani Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Rani Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Rani Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rani Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rani Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rani Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rani Therapeutics Outstanding Bonds
Rani Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Rani Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Rani bonds can be classified according to their maturity, which is the date when Rani Therapeutics Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Rani Therapeutics Predictive Daily Indicators
Rani Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Rani Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Rani Therapeutics Corporate Filings
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 17th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 16th of October 2024 Other Reports | ViewVerify | |
8K | 11th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 6th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 23rd of July 2024 Other Reports | ViewVerify | |
8K | 12th of July 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 24th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Rani Therapeutics Forecast Models
Rani Therapeutics' time-series forecasting models are one of many Rani Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Rani Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Rani Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Rani Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Rani shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Rani Therapeutics. By using and applying Rani Stock analysis, traders can create a robust methodology for identifying Rani entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (17.57) | (18.45) | |
| Operating Profit Margin | (17.09) | (17.95) | |
| Net Loss | (17.59) | (18.46) |
Current Rani Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Rani analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Rani analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 22.25 | Strong Buy | 8 | Odds |
Most Rani analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Rani stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Rani Therapeutics, talking to its executives and customers, or listening to Rani conference calls.
Rani Stock Analysis Indicators
Rani Therapeutics Holdings stock analysis indicators help investors evaluate how Rani Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Rani Therapeutics shares will generate the highest return on investment. By understating and applying Rani Therapeutics stock analysis, traders can identify Rani Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 27.5 M | |
| Long Term Debt | 24.5 M | |
| Common Stock Shares Outstanding | 25.5 M | |
| Total Stockholder Equity | 12.9 M | |
| Tax Provision | -41 K | |
| Property Plant And Equipment Net | 6.8 M | |
| Cash And Short Term Investments | 48.5 M | |
| Cash | 5.9 M | |
| Accounts Payable | 648 K | |
| Net Debt | 24.2 M | |
| 50 Day M A | 2.3063 | |
| Total Current Liabilities | 8 M | |
| Other Operating Expenses | 66.1 M | |
| Non Current Assets Total | 7.1 M | |
| Non Currrent Assets Other | 246 K | |
| Stock Based Compensation | 19 M |
Complementary Tools for Rani Stock analysis
When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |